Common and distinctive pathogenetic features of arteriovenous malformations in hereditary hemorrhagic telangiectasia 1 and hereditary hemorrhagic telangiectasia 2 animal models - Brief report

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 10, 2014, Pages 2232-2236

  Garrido Martin, Eva M ^a   Nguyen, Ha Long ^a   Cunningham, Tyler A ^a   Choe, Se Woon ^a,c   Jiang, Zhihua ^b   Arthur, Helen M ^d   Lee, Young Jae ^e   Oh, S Paul ^a,e  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Tongmyong University   (South Korea)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e Gachon University College of Medicine   (South Korea)

Author keywords

Alk1 protein, mouse; Arteriovenous malformations; Endoglin protein, mouse; Endothelial cells; Myocytes, smooth muscle; Telangiectasia, hereditary hemorrhagic

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; CRE RECOMBINASE; ENDOGLIN; TAMOXIFEN; ACTIVIN RECEPTOR 1; ACVRL1 PROTEIN, MOUSE; ENDOGLIN PROTEIN, MOUSE; SIGNAL PEPTIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS MALFORMATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; HEART LEFT VENTRICLE; HEREDITARY HEMORRHAGIC TELANGIECTASIA 1; HEREDITARY HEMORRHAGIC TELANGIECTASIA 2; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; OXYGEN SATURATION; PROTEIN DEPLETION; PROTEIN FUNCTION; RENDU OSLER WEBER DISEASE; SMOOTH MUSCLE FIBER; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DEFICIENCY; DISEASE MODEL; ENDOTHELIUM CELL; FEMALE; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; TIME; VASCULAR SMOOTH MUSCLE; WOUND HEALING;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; ARTERIOVENOUS MALFORMATIONS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TIME FACTORS; WOUND HEALING;

EID: 84914171026     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303984     Document Type: Article

References (15)

1. Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet. 2009;17:860-871.
2. Fleetwood IG, Steinberg GK. Arteriovenous malformations. Lancet. 2002;359:863-873.
3. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010;24:203-219.
4. Park SO, Wankhede M, Lee YJ, Choi EJ, Fliess N, Choe SW, Oh SH, Walter G, Raizada MK, Sorg BS, Oh SP. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest. 2009;119:3487-3496.
5. Park SO, Lee YJ, Seki T, Hong KH, Fliess N, Jiang Z, Park A, Wu X, Kaartinen V, Roman BL, Oh SP. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood. 2008;111:633-642.
6. Niessen K, Zhang G, Ridgway JB, Chen H, Yan M. ALK1 signaling regulates early postnatal lymphatic vessel development. Blood. 2010;115:1654-1661.
7. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931-1937.
8. Milton I, Ouyang D, Allen CJ, Yanasak NE, Gossage JR, Alleyne CH Jr, Seki T. Age-dependent lethality in novel transgenic mouse models of central nervous system arteriovenous malformations. Stroke. 2012;43:1432-1435.
9. Choi EJ, Chen W, Jun K, Arthur HM, Young WL, Su H. Novel brain arteriovenous malformation mouse models for type 1 hereditary hemorrhagic telangiectasia. PLoS One. 2014;9:e88511.
10. Badea TC, Wang Y, Nathans J. A noninvasive genetic/pharmacologic strategy for visualizing cell morphology and clonal relationships in the mouse. J Neurosci. 2003;23:2314-2322.
11. Göthert JR, Gustin SE, van Eekelen JA, Schmidt U, Hall MA, Jane SM, Green AR, Göttgens B, Izon DJ, Begley CG. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood. 2004;104:1769-1777.
12. Wirth A, Benyo Z, Lukasova M, Leutgeb B, Wettschureck N, Gorbey S, Orsy P, Horvath B, Maser-Gluth C, Greiner E, Lemmer B, Schuetz N, Gutkind S, Offermanns S. G(12)-G(13)-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nature Medicine. 2008;14:64-68.
13. Yoshimatsu Y, Lee YG, Akatsu Y, et al. Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression. Proc Natl Acad Sci U S A. 2013;110:18940-18945.
14. Sorg BS, Moeller BJ, Donovan O, Cao Y, Dewhirst MW. Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. J Biomed Opt. 2005;10:44004.
15. Choi EJ, Walker EJ, Shen F, Oh SP, Arthur HM, Young WL, Su H. Minimal homozygous endothelial deletion of Eng with VEGF stimulation is sufficient to cause cerebrovascular dysplasia in the adult mouse. Cerebrovasc Dis. 2012;33:540-547.